Palo Alto Medical Foundation Health Care

Summary

Palo Alto Medical Foundation Health Care is a medical facility located in Palo Alto, California. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer and other specialties. Palo Alto Medical Foundation Health Care is involved with conducting 182 clinical trials across 312 conditions. There are 13 research doctors associated with this hospital, such as Ari Baron, MD, Christopher Jones, Deepti Behl, and Kristie A. Bobolis.

Top PIs

Clinical Trials running at Palo Alto Medical Foundation Health Care

Lung Cancer

Pancreatic Cancer

Breast Cancer

Ovarian Cancer

Kidney Cancer

Non-Small Cell Lung Cancer

Esophageal cancer

Breast cancer

Glioblastoma

Multiple Myeloma

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.

Recruiting

2 awards

Phase 3

27 criteria

High-Dose Radiation + Chemotherapy and Immunotherapy

for Non-Small Cell Lung Cancer

This trial tests whether adding a precise form of radiation therapy to the usual treatment improves outcomes for patients with advanced lung cancer that can't be operated on. The goal is to see if this combination helps patients live longer and prevents cancer from worsening. This form of radiation therapy has shown promise in improving survival rates in patients with various stages of lung cancer.

Recruiting

2 awards

Phase 3

14 criteria

Amivantamab

for Non-Small Cell Lung Cancer

This phase II Expanded Lung-MAP treatment trial tests how well amivantamab-subcutaneous (SC) works in treating patients patients with MET amplification non-small cell lung cancer. Amivantamab-SC is a drug that reduces extra copies of the MET gene, a change present in your tumor. Giving amivantamab-SC may lower the chance of the growth or spread of advanced non-small cell lung cancer that has extra copies of the MET gene in the tumor.

Recruiting

1 award

Phase 2

16 criteria